http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#Head
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#assertion
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#provenance
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#pubinfo
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#assertion
http://purl.obolibrary.org/obo/DOID_9952
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_9952
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00631
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#association
http://www.w3.org/2000/01/rdf-schema#label
clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens this indication is based upon response rate there are no trials verifying an improvement in disease related symptoms or increased survival with clofarabine injection clofarabine injection is a purine nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens this indication is based upon response rate there are no trials verifying an improvement in disease related symptoms or increased survival with clofarabine injection 1
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00631
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#provenance
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#pubinfo
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#sig
http://purl.org/nanopub/x/hasSignature
B3GI2fl6Y1C4IFz15oqvnEqoK3QBdX1j67sMJoaQy8iButSKBFxfrO3KqJEvixtA9YY2h+hWM3Wd3JMFCHTZJPASmGhixMas0g5vm0X5Kh2bKQ7EYCas2Kku5irrF2gynNByptcJuWfPqy0HUQLCVL1iROwUC2ySFtye1rwixyM=
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY
http://purl.org/dc/terms/created
2021-06-29T08:38:39.855+02:00
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RA4KxSEUImeANdFS-dzoL84TYCs2geqYuG3Vz1TPvjBDY
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs